Cizzle Biotechnology Holdings PLC Total Assets
Cizzle Biotechnology Holdings PLC total assets. Based on the latest financial reports, Cizzle Biotechnology Holdings PLC (CIZ) holds total assets worth GBX257.00K GBX (≈ $31.27 USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see CIZ market cap overview for the company's overall valuation and market capitalisation.
Total Assets of Cizzle Biotechnology Holdings PLC (2006–2024)
Total assets of Cizzle Biotechnology Holdings PLC from 2006 to 2024. This chart illustrates how Cizzle Biotechnology Holdings PLC's total assets have evolved over time, based on quarterly financial data. See current stock price of Cizzle Biotechnology Holdings PLC for real-time trading data and today's change.
Cizzle Biotechnology Holdings PLC - Asset Composition Analysis
Cizzle Biotechnology Holdings PLC Total Assets Breakdown (December 2024)
Cizzle Biotechnology Holdings PLC total assets breakdown as of December 2024. Cizzle Biotechnology Holdings PLC's total assets of GBX257.00K consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (GBX) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | GBX0.00 | 74.2% |
| Accounts Receivable | GBX103.00K | 20.9% |
| Inventory | GBX2.00K | 0.4% |
| Property, Plant & Equipment | GBX0.00 | 0.0% |
| Intangible Assets | GBX0.00 | 0.0% |
| Goodwill | GBX0.00 | 0.0% |
Asset Composition Trend (2006–2024)
This chart illustrates how Cizzle Biotechnology Holdings PLC's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore working capital to net assets of Cizzle Biotechnology Holdings PLC to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Cizzle Biotechnology Holdings PLC's current assets represent 100.0% of total assets in 2024, an increase from 65.8% in 2006.
- Cash Position: Cash and equivalents constituted 74.2% of total assets in 2024, up from 24.0% in 2006.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 13.0% in 2006.
- Asset Diversification: The largest asset category is accounts receivable at 20.9% of total assets.
Cizzle Biotechnology Holdings PLC Competitors by Total Assets
Key competitors of Cizzle Biotechnology Holdings PLC based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940
|
Korea | ₩12.65 Trillion |
|
Abivax SA
PA:ABVX
|
France | €547.14 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Sinocelltech Group Ltd
SHG:688520
|
China | CN¥3.76 Billion |
|
Inner Mongolia Furui Med Sci
SHE:300049
|
China | CN¥3.47 Billion |
|
Mineralys Therapeutics, Inc. Common Stock
NASDAQ:MLYS
|
USA | $667.85 Million |
|
GH Research PLC
NASDAQ:GHRS
|
USA | $372.35 Million |
Cizzle Biotechnology Holdings PLC - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.48 | 7.16 | 33.00 |
| Quick Ratio | 0.48 | 7.98 | 33.02 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | GBX-278.00K | GBX794.00K | GBX1.86 Million |
Cizzle Biotechnology Holdings PLC - Advanced Valuation Insights
This section examines the relationship between Cizzle Biotechnology Holdings PLC's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 77.34 |
| Latest Market Cap to Assets Ratio | 0.11 |
| Asset Growth Rate (YoY) | -70.9% |
| Total Assets | GBX492.00K |
| Market Capitalization | $55.46K USD |
Valuation Analysis
Below Book Valuation: The market values Cizzle Biotechnology Holdings PLC's assets below their book value (0.11x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Cizzle Biotechnology Holdings PLC's assets decreased by 70.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Cizzle Biotechnology Holdings PLC (2006–2024)
The table below shows the annual total assets of Cizzle Biotechnology Holdings PLC from 2006 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | GBX492.00K ≈ $59.86 |
-70.94% |
| 2023-12-31 | GBX1.69 Million ≈ $205.99 |
-39.21% |
| 2022-12-31 | GBX2.79 Million ≈ $338.85 |
+141.13% |
| 2021-12-31 | GBX1.16 Million ≈ $140.53 |
+1183.33% |
| 2020-12-31 | GBX90.00K ≈ $10.95 |
+446.22% |
| 2019-12-31 | GBX16.48K ≈ $2.00 |
-82.84% |
| 2018-12-31 | GBX96.00K ≈ $11.68 |
-96.89% |
| 2017-12-31 | GBX3.08 Million ≈ $375.36 |
-31.29% |
| 2016-12-31 | GBX4.49 Million ≈ $546.30 |
-11.84% |
| 2015-12-31 | GBX5.09 Million ≈ $619.67 |
-35.14% |
| 2014-12-31 | GBX7.85 Million ≈ $955.36 |
+6.29% |
| 2013-12-31 | GBX7.39 Million ≈ $898.78 |
-9.25% |
| 2012-12-31 | GBX8.14 Million ≈ $990.40 |
+33.49% |
| 2011-12-31 | GBX6.10 Million ≈ $741.95 |
+20.13% |
| 2010-12-31 | GBX5.08 Million ≈ $617.60 |
+328.35% |
| 2009-12-31 | GBX1.19 Million ≈ $144.18 |
-47.10% |
| 2008-12-31 | GBX2.24 Million ≈ $272.54 |
-28.30% |
| 2007-12-31 | GBX3.12 Million ≈ $380.10 |
+242.92% |
| 2006-12-31 | GBX911.00K ≈ $110.84 |
-- |
About Cizzle Biotechnology Holdings PLC
Cizzle Biotechnology Holdings Plc, together with its subsidiaries, operates as a cancer diagnostics company in the United Kingdom. It develops a non-invasive blood test for early lung cancer detection using CIZ1B biomarker technology. The company was formerly known as Cizzle Biotechnology Limited and changed its name to Cizzle Biotechnology Holdings Plc in May 2021. Cizzle Biotechnology Holdings … Read more